Sprint Bioscience AB (OSTO:SPRINT) Moat Score: 0/10 (As of Jul. 03, 2026)


OSTO:SPRINT Sprint Bioscience AB OSTO:SPRINT
32 GF Score
Price kr4.06
GF Value kr2.18
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Sprint Bioscience AB Moat Score?

Sprint Bioscience AB has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Sprint Bioscience AB has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Sprint Bioscience AB might have No Moat - No discernible moat.

Sprint Bioscience AB  (OSTO:SPRINT) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Sprint Bioscience AB Moat Score Related Terms

OSTO:SPRINT
32GF Score
Sprint Bioscience AB OSTO:SPRINT
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sprint Bioscience AB (OSTO:SPRINT) Overvalued in 2026?

Based on GuruFocus' analysis, Sprint Bioscience AB stock appears to be overvalued. The current stock price of kr4.06 is trading 86.2% above its estimated GF Value™ of kr2.18. GuruFocus considers Sprint Bioscience AB to be Significantly Overvalued.

Key valuation signals for OSTO:SPRINT:

  • Moat Score: 0
  • GF Value™: kr2.18 vs. price of kr4.06 (86.2% above fair value)
  • GF Score™: 32/100 with 4 warning signs

No single metric tells the full story. See the OSTO:SPRINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sprint Bioscience AB Business Description

Other Exchanges 5JA1:Germany
Address Halsovagen 7, floor 8, elevator A, Novum, Huddinge, SWE, 141 57
Sprint Bioscience AB is a pharmaceutical company focused on developing drug candidates that can contribute to new treatments for cancer. Its product portfolio includes VRK1, VPS34, PETRA01, TREX1, NNMT, STK25, and DCPS. The company receives revenue for out-licensing drug programs, which include the development of a drug candidate.
32GF Score

Get the complete analysis for OSTO:SPRINT

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr4.06
Price
kr2.18
GF Value